The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
about
Improving natural killer cell cancer immunotherapyA phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
P2860
The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The optimized anti-CD20 monocl ...... Waldenström macroglobulinemia.
@en
The optimized anti-CD20 monocl ...... Waldenström macroglobulinemia.
@nl
type
label
The optimized anti-CD20 monocl ...... Waldenström macroglobulinemia.
@en
The optimized anti-CD20 monocl ...... Waldenström macroglobulinemia.
@nl
prefLabel
The optimized anti-CD20 monocl ...... Waldenström macroglobulinemia.
@en
The optimized anti-CD20 monocl ...... Waldenström macroglobulinemia.
@nl
P2093
P2860
P50
P1433
P1476
The optimized anti-CD20 monocl ...... Waldenström macroglobulinemia
@en
P2093
Christophe de Romeuf
Linda Herbi
Nabih Azar
Patrick Bonnemye
Rémi Urbain
Vincent Vieillard
Véronique Leblond
P2860
P304
P356
10.3324/HAEMATOL.2014.118083
P577
2014-12-31T00:00:00Z